Omeros

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Omeros and other ETFs, options, and stocks.

About OMER

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. 

CEO
Gregory A. Demopulos
CEOGregory A. Demopulos
Employees
202
Employees202
Headquarters
Seattle, Washington
HeadquartersSeattle, Washington
Founded
1994
Founded1994
Employees
202
Employees202

OMER Key Statistics

Market cap
551.93M
Market cap551.93M
Price-Earnings ratio
-4.66
Price-Earnings ratio-4.66
Dividend yield
Dividend yield
Average volume
13.40M
Average volume13.40M
High today
$9.71
High today$9.71
Low today
$7.96
Low today$7.96
Open price
$9.60
Open price$9.60
Volume
6.99M
Volume6.99M
52 Week high
$13.60
52 Week high$13.60
52 Week low
$2.95
52 Week low$2.95

OMER News

TipRanks 1d
Omeros announces publication of narsoplimab survival benefits in TA-TMA

Omeros (OMER) announced the publication of a peer-reviewed manuscript in an American Society of Hematology journal, Blood Advances. The manuscript details survi...

The Motley Fool 2d
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now?

Find out if the deal Omeros announced is enough of a reason to buy this stock. Shares of Omeros (OMER 154.15%) finished Oct. 14's trading session at $4.10 per...

A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now?
Benzinga 2d
Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal

Biotech breakthroughs are reshaping the pharmaceutical landscape, sparking lucrative deals and redefining the future of rare disease treatment. Omeros Corporati...

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal

More OMER News

Nasdaq 2d
Novo Nordisk Signs Purchase And License Deal For Omeros's Zaltenibart

(RTTNews) - Novo Nordisk A/S (NVO), along with Omeros Corp., Wednesday announced a definitive asset purchase and license agreement for the candidate drug zalten...

Novo Nordisk Signs Purchase And License Deal For Omeros's Zaltenibart
TipRanks 2d
Omeros Signs Major Deal with Novo Nordisk

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

Yahoo Finance 2d
Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart - Yahoo Finance

...

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart - Yahoo Finance

People also own

Based on the portfolios of people who own OMER. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.